DNV 3
Alternative Names: DNV-3Latest Information Update: 13 Jun 2022
Price :
$50 *
At a glance
- Originator Zhejiang Shimai Pharmaceutical
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Lymphoma; Solid tumours
- Phase I Multiple sclerosis
Most Recent Events
- 09 Jun 2022 Phase-I clinical trials in Multiple sclerosis in China (Parenteral) before June 2022 (Zhejiang Shimai Pharmaceutical pipeline, June 2022)
- 09 Jun 2022 Phase-II clinical trials in Lymphoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral) before June 2022 (Zhejiang Shimai Pharmaceutical pipeline, June 2022)
- 09 Jun 2022 Phase-II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral) before June 2022 (Zhejiang Shimai Pharmaceutical pipeline, June 2022)